Coronary Atherosclerotic Heart Disease
Conditions
Brief summary
Apply a new operation method of Left Internal Mammary Artery (LIMA)-Greater Saphenous Vein (GSV)-SCVBG to the treatment of patients with diffuse coronary artery disease,through clinical randomized controlled study,compared with patients of bilateral internal mammary artery (BIMA)-SCVBG and evaluate both of therapeutic effects and prognosis.
Interventions
PROCEDUREA method of operation: LIMA-GSV-SCVBG
On the experimental group,We treat patients with the operation of LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein
PROCEDUREBIMA-SCVBG
On the other group, We treat patients with the operation of bilateral internal mammary artery composited LIMA-Right Mammary Artery（RIMA） y graft and anastomose the Right Mammary Artery(RIMA) with selective coronary vein.
Sponsors
Beijing Anzhen Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
No minimum to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients with right coronary artery diffuse lesions:Right coronary artery lumen≤1mm，Lesion lengths ≥20mm or multiple segment lesions. * Patients of coronary artery bypass grafting (CABG) that can't be treated through endarterectomy. * Patients ≤ 70 years old. * All enrolled patients must being signed the informed consent.
Exclusion criteria
* Severe heart failure(ejection fraction under 35%) or non coronary atherosclerotic heart disease patients such as combined with severe valvular heart disease. * Patients with acute myocardial infarction. * Assistant examinations indicate that the bridge vessels can't be used；The left subclavian artery stenosis and/or LIMA lesions；RIMA lesions；varicosis of both great saphenous vein.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The patency rate of bridge vessels and selective coronary vein | 1-3 years | We will assess the patency rate during a follow-up of 1 year, and continue to follow up to 3 years after the end of the project |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Main adverse cardiovascular and cerebrovascular events | 1-3 years | We will follow up the main adverse cardiovascular and cerebrovascular events ( death, myocardial infarction, stroke and repeated revascularization) 7 days, 1 month, 3 months, 6 months and 1 year after the operation and continue to 3 years. |
| Wound complications | 1-3 years | We will follow up the wound complications (sternum and mediastinal infection, incision infection, fat liquefaction) 7 days, 1 month, 3 months, 6 months and 1 year after the operation and continue to 3 years. |
Countries
China
Outcome results
None listed